Overview of Levikar-Mitim

Property	Description
Active Ingredient	Levocarnitine (L-Carnitine)
Form	Oral Solution, Tablets, Injectable Solution
Pharmacological Class	Amino Acid Supplement; Alimentary Tract and Metabolism Product
General Purpose	Supports cellular energy metabolism
Origin	Naturally Occurring Amino Acid Derivative

Levikar-Mitim is a prescription medication whose sole active ingredient is Levocarnitine, a substance identified as a naturally occurring amino acid derivative. It is classified within the pharmacological class of Amino Acid Supplements and falls under the Anatomical Therapeutic Chemical (ATC) grouping for agents affecting metabolism. This classification is based on its recognized role in metabolic pathways.

This medicine is a preparation of pure L-Carnitine that functions as an essential cofactor in the body. The composition is deliberately designed to provide the specific beneficial (R)-Carnitine inner salt, as the D-isomer is known to competitively interfere with the molecule's essential transport function, a critical distinguishing factor from non-pharmaceutical supplements.

Pharmacological Class and Function

Levikar-Mitim is supplied as a single-ingredient product in multiple pharmaceutical dosage forms, including Oral Solution, Tablets, and an Injectable Solution for parenteral administration. Its primary general purpose is to support the body's cellular energy metabolism by correcting low carnitine levels typically seen in conditions of established deficiency.

At the core of its utility, Levocarnitine serves as a vital carrier molecule that actively transports long-chain fatty acids into the mitochondria, the cell's energy-producing compartments. Levikar-Mitim facilitates this transport, which supports the continuous flow of fuel for fatty acid oxidation. This action enables high-energy tissues like the cardiac and skeletal muscles to generate power and maintain energy production.

Regulatory References

Carnitine - Health Professional Fact Sheet - NIH Office of Dietary Supplements

What side effects are possible with Levikar-Mitim?

The following information is based on the official safety documents, such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC). This descriptive content details the drug's official risk profile and is not clinical advice.

Documented Adverse Reactions

The most frequently documented adverse reactions, generally classified as Common in regulatory sources, are typically related to the Gastrointestinal System. These include transient nausea, vomiting, abdominal cramps, and diarrhea. A distinguishing, dose-related effect noted in official labeling is the occurrence of body odor, sometimes described as fishy. These effects are often linked to dosage and may diminish with adjustments.

Reactions affecting the Nervous System include reported headache and dizziness. Of greater clinical significance, seizures have been reported in patients receiving levocarnitine. For individuals with a pre-existing seizure disorder, the regulatory label notes that an increase in the frequency and/or severity of seizures has been documented during the course of treatment.

Serious Safety Considerations

The official profile identifies Serious Hypersensitivity Reactions as a key safety concern. These uncommon events include anaphylaxis, laryngeal edema, and bronchospasm, which are predominantly reported following intravenous administration, particularly in patients with end-stage renal disease (ESRD).

Population-Specific Risk (Severe Renal Impairment): Chronic, high-dose oral administration of this medicine in patients with severely compromised renal function or ESRD on dialysis is associated with a safety concern. Due to impaired clearance, there is a risk of accumulation of potentially toxic metabolites (trimethylamine and trimethylamine-N-oxide) over time. Furthermore, concomitant use with coumarin anticoagulants (e.g., Warfarin) has been associated with reports of an increased International Normalized Ratio (INR), a finding that requires attention to coagulation parameters.

Overdose and Emergency Response

Overdose and when to seek help

Category	Regulatory Statement / Documented Fact
Documented overdose presentations	The most consistent clinical manifestation noted in association with large doses of levocarnitine is diarrhea.
Physiological systems affected	Gastrointestinal system (diarrhea).
Dose-related or exposure-related factors	Large doses may cause diarrhea.
Population-specific overdose notes	Chronic administration of high oral doses in patients with severely compromised renal function or on dialysis may lead to the accumulation of potentially toxic metabolites (trimethylamine and trimethylamine-N-oxide).
Emergency-response statements	Overdosage should be treated with supportive care.
When immediate medical help is required	If too much levocarnitine has been used, get medical help right away (call 911 or a Poison Control center).

Overdose classifications (high-level)

Category	Regulatory Statement / Documented Fact
Severity classification	The official labeling states: There have been no reports of toxicity from levocarnitine overdosage.
Regulatory basis	Based on U.S. FDA and European regulatory prescribing information.
Overdose-context constraints	No specific antidote is known for treatment of overdosage.

Official overdose statements:

No reports of toxicity from levocarnitine overdosage have been observed in regulatory records.
The most common clinical presentation cited for large doses is diarrhea.
Individuals who have used too much must get medical help right away (call 911 or a Poison Control center).
Levocarnitine is a substance easily removed from plasma by dialysis.
Management of overdosage is mandated to be treated with supportive care.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose profile as generally lacking acute systemic toxicity reports, with diarrhea being the primary symptom noted for large doses. Despite the lack of severe acute symptoms, immediate medical attention is required. The established procedural management involves supportive care and the use of dialysis for removal due to the drug's properties.

Therapeutic Uses of Levikar-Mitim

What Levikar-Mitim Treats: Main Uses and Benefits

Levikar-Mitim is commonly used for conditions characterized by symptoms related to systemic carnitine deficiency. Its application is relevant for the acute and chronic management of conditions such as primary systemic carnitine deficiency and secondary carnitine deficiency, including those resulting from inborn errors of metabolism, such as organic acidemias.

The medication is applied to support crucial metabolic balance and may assist in supporting organ function during the management of progressive deficiency. It helps address symptom clusters that may become intense or disruptive, specifically chronic muscle weakness, fatigue, and poor muscle tone. It is also relevant for easing symptoms linked to functional stress, notably cardiomyopathy and poor cardiac function tied to carnitine deficit.

“The use of this medication is relevant for managing symptoms associated with profound systemic deficits.”

Quick Fact: Relief for Energy and Functional Stability

Levikar-Mitim is applied across conditions presenting with systemic or localized discomfort and is helpful in situations where symptoms create noticeable functional strain. It provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Levikar-Mitim's eligibility profile is based entirely on official regulatory documentation and is defined by the underlying carnitine deficiency status and certain population-specific restrictions. The manufacturer has listed no absolute contraindications in the drug's official label.

Eligibility Scope

Category	Status According to Labeling
Use Allowed (Primary Indication)	Patients with diagnosed primary or secondary systemic carnitine deficiency. Use of the injection is established for patients with End-Stage Renal Disease (ESRD) on dialysis.
Use Not Recommended	Chronic high-dose oral use is not recommended for patients with severe renal dysfunction or ESRD on dialysis due to the risk of accumulating potentially toxic metabolites.
Conditional Use/Caution	Caution is advised for patients with a history of seizure activity, as an increase in seizure frequency or severity has been reported. Use during pregnancy (Category B) is only if clearly needed, as adequate human studies are not available. For nursing mothers, the risks must be weighed against maternal benefits.
Age Groups	Use is established for pediatric patients (infants and children) and for adults. No difference in safety is expected for older adults.

Resulting Eligibility Structure

Official documents define eligibility primarily by the presence of a carnitine deficiency. Chronic oral use is restricted in severe kidney impairment, while use in patients with a history of seizures, pregnant women, and nursing mothers is permitted under specific cautionary or conditional status.

What should I know about interactions with other medicines?

Levikar-Mitim (Levocarnitine) has documented interaction patterns with specific medicines and substances, as noted in official government regulatory labeling.

Drug-Drug Interaction Outcomes

Co-administration with coumarin derivative anticoagulants, such as Warfarin, is officially associated with reports of an increase in the International Normalized Ratio (INR). This pharmacodynamic effect necessitates procedural monitoring of the INR when treatment with Levikar-Mitim is initiated or following a dose adjustment.

Interactions Affecting Drug Exposure

The regulatory profile notes that certain anticonvulsant medications, including Valproic Acid, Phenobarbital, and Phenytoin, are documented to reduce the plasma concentration of Levocarnitine. This reduction in drug exposure is similarly noted to occur with the herbal product Rose Hips.

Formal Interaction Restrictions

Regulatory documents classify the non-therapeutic isomers D-carnitine and DL-carnitine as substances that competitively interfere with the active transport function of pharmaceutical Levocarnitine. The co-administration of these substances is therefore strictly restricted. No mandatory dose separation rules for timing are documented with other medicines.

Population-Specific Caution

A specific caution concerning metabolite accumulation exists for patients with severe renal impairment, including those on End-Stage Renal Disease (ESRD) dialysis. The chronic administration of high oral doses is associated with the accumulation of the metabolites trimethylamine (TMA) and trimethylamine-N-oxide (TMAO) due to the impaired excretion in this population.

Mechanism of Action

Facilitation of Mitochondrial Fatty Acid Transport

Levikar-Mitim's mechanism is defined by its role as an obligate cofactor for the Carnitine Palmitoyltransferase (CPT) system, an enzyme-transporter network spanning the inner mitochondrial membrane. This interaction is required to physically shuttle long-chain fatty acids into the mitochondrial matrix, enabling their subsequent utilization as fuel. Through this influence on the CPT/CAT transport step, the molecule facilitates the supply of energy substrate to tissues, such as skeletal and cardiac muscle, that demonstrate a high reliance on fat metabolism.

Influence on Cellular Bioenergetic Pathways

Once transported, the fatty acids enter the β-oxidation pathway, leading to the efficient generation of Acetyl-CoA for the TCA cycle and subsequent ATP production. The mechanism influences the process of cellular energy metabolism by enabling the utilization of available lipid fuels. Additionally, Levocarnitine is involved in the metabolic handling of inhibitory acyl-CoA species, forming excretable acylcarnitines. This molecular action maintains the operational state of downstream energy-generating enzymes.

Dosage and Administration Information

How to Use Levikar-Mitim

This section describes the high-level principles of administering Levikar-Mitim, outlining the routes, dosing patterns, and specific use conditions.

Administration Overview

Levikar-Mitim (Levocarnitine) is administered through two primary routes, selected based on the clinical context:

Oral: Used for chronic management and provided in tablet (e.g., 330 mg) and oral solution (e.g., 1 g/10 mL) forms.
Intravenous (IV): Used for acute metabolic crises and for patients with End-Stage Renal Disease (ESRD) undergoing hemodialysis, supplied as an injectable solution.

Dosing and Frequency Principles

Administration involves titration within established ranges. The maximum recommended oral maintenance dose for adults is generally 3 grams per day.

Context	Starting Dose Principle	Frequency Pattern
Adult Oral (Chronic)	Initial dose typically starting around 1 g/day.	Administered in two to three divided doses daily, or once daily initially for the solution form.
Pediatric Oral	Based on body weight, starting at 50 mg/kg/day in divided doses.	Daily, typically divided doses, not to exceed 3 g/day.
IV (Acute Crisis)	Initial loading dose of 50 mg/kg/dose.	Administered at specified intervals, often every 3 to 4 hours, but not less than every 6 hours.

Contextual Use Requirements

Specific conditions apply for proper administration:

Timing: Oral forms are generally taken with or immediately after meals to improve patient tolerance.
Preparation: The oral solution can be dissolved in water, juice, or liquid food prior to slow consumption.
ESRD Patients: Dosing is often tied to the dialysis schedule, with an IV dose of 10 to 20 mg/kg of dry body weight administered post-dialysis. The IV route is preferred for chronic use in patients with severe renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Levikar-Mitim

The research base for Levocarnitine (Levikar-Mitim) focuses on correcting established carnitine deficiencies, with evidence structured by the underlying cause. This overview outlines what has been studied and what remains uncertain, based on official regulatory and scientific literature.

1. Research Evidence for Primary Systemic Carnitine Deficiency

Due to the rarity of this genetic condition, the evidence is largely constructed from clinical observations and controlled case series across various age groups. Research explored patterns associated with the medicine's use in this condition, reporting changes in plasma carnitine levels and specific markers of organ function. However, data are not derived from large-scale randomized trials, and long-term functional outcomes are primarily tracked through ongoing clinical observation.

2. Research Evidence for Secondary Carnitine Deficiency in Inborn Errors of Metabolism

This research primarily involves controlled trials and long-term observational studies in pediatric populations with specific metabolic disorders, such as organic acidemias. Studies explored the relationship between the medicine and toxic metabolite levels, reporting how concentrations of these compounds evolved during the study period. While evidence contributes to the broader evidence landscape, results apply mainly to the specific disease subtypes studied, and generalization to other conditions remains limited.

3. Research Evidence for Carnitine Deficiency in Kidney Disease (Dialysis)

Controlled trials, including Randomized Controlled Trials (RCTs), have examined the use of the medicine in adult patients undergoing hemodialysis. Research consistently showed patterns related to an increase in plasma carnitine concentrations. However, when studies examined subjective outcomes like chronic fatigue or muscle weakness, the findings were mixed, indicating that certainty remains low for these specific functional benefits due to the complexity of the underlying renal disease.

4. Current Evidence Gaps and Areas of Uncertainty

Across all indications, research highlights that follow-up durations are often limited, and data on long-term effects and durability are not fully established. Comparative evidence is lacking for some applications, and findings on patient-reported outcomes show variability across studies.

Frequently Asked Questions (FAQ)

Common questions about Levikar-Mitim (FAQ)

Q: What is the main reason a doctor might prescribe Levikar-Mitim?

A: According to regulatory documents, Levikar-Mitim (Levocarnitine) is indicated for treating conditions caused by low carnitine levels. This includes primary systemic carnitine deficiency and secondary carnitine deficiency linked to inborn errors of metabolism. The injectable form is also used for patients with End-Stage Renal Disease who are undergoing hemodialysis.

Q: How quickly should I expect to see any kind of change after starting Levikar-Mitim?

A: Official pharmacological data indicates that the highest concentration of the medicine in the blood generally occurs about 3.3 hours after an oral dose. The medicine then stays in the body for an extended period, with a mean half-life of about 17.4 hours. The evaluation of changes in clinical symptoms is typically performed by the prescribing physician during follow-up visits.

Q: Is Levikar-Mitim considered a short-term or long-term treatment?

A: Levikar-Mitim is commonly used for the chronic management of carnitine deficiencies, meaning it is intended for long-term use in these conditions. However, the injectable form is also used for short-term situations, such as managing acute metabolic crises until the patient stabilizes.

Q: Are the common side effects listed for Levikar-Mitim temporary?

A: Official safety information notes that the most frequently reported gastrointestinal effects, such as nausea, vomiting, and diarrhea, are often dose-related. These effects may lessen or resolve when the dosage is reviewed and potentially adjusted by a healthcare provider, according to label guidance.

Q: What happens if I miss a dose of Levikar-Mitim?

A: Patient information generally describes a protocol where a missed dose is taken if remembered shortly after the scheduled time. If it is close to the next scheduled time, the advice is typically to skip the missed dose. Official guidance notes that patients should avoid taking extra medicine to compensate for a missed dose.

Q: Can taking Levikar-Mitim make me feel more tired than usual?

A: Yes, some safety reports have listed fatigue (feeling tired), weakness, or a tingling sensation among the less common adverse reactions associated with the medicine. Any changes in a patient's energy levels are typically matters for discussion with their healthcare provider.

Q: Is Levikar-Mitim available as a generic medicine?

A: Yes, the active ingredient in Levikar-Mitim, Levocarnitine, is generally available in generic forms for prescription use.

Q: Is Levikar-Mitim known to cause any skin-related issues?

A: Official adverse reaction reports include various skin-related issues, such as rash and pruritus (itching). More serious, but rare, hypersensitivity reactions like hives have also been reported in safety documents.

Q: What should I know about Levikar-Mitim if I have liver problems?

A: Levocarnitine plays a role in metabolic processes involving the liver, which is one of the organs responsible for carnitine production in the body. While the medicine may not be formally restricted for liver issues, patients with pre-existing conditions typically inform their physician to ensure appropriate monitoring.

Q: Do certain foods or drinks need to be avoided when using Levikar-Mitim?

A: The official drug label specifically notes that the herbal product Rose Hips has been documented to reduce the amount of Levocarnitine in the blood. Beyond this, specific dietary restrictions are not typically listed, as the medicine is generally taken along with or after meals.

Q: How long does the primary effect of one dose of Levikar-Mitim last?

A: The mean apparent terminal elimination half-life of levocarnitine is approximately 17.4 hours. This means the time between doses is set by a healthcare provider with the intent of maintaining consistent levels of the medicine in the body to manage the carnitine deficiency.

Q: Why are there different strengths of Levikar-Mitim available?

A: Official dosing information states that different strengths (like tablets, oral solutions, and injections) and formulations are manufactured to allow for flexible use. This helps healthcare providers tailor the dose based on the patient's body weight, age, and whether the treatment is for chronic management or an acute crisis.

Q: Can Levikar-Mitim be split or crushed if I have trouble swallowing pills?

A: The tablets are generally intended to be swallowed whole and official information states they are not to be crushed or chewed unless specifically instructed otherwise. If swallowing is difficult, the oral solution form is often an option, as it is designed to be mixed with water, juice, or liquid food.

Q: Are there any known interactions between Levikar-Mitim and alcohol?

A: Alcohol is not listed as a formal drug interaction in the official product information’s drug interaction section. However, general guidance typically recommends that patients discuss the use of all substances, including alcohol, with their doctor or pharmacist.

Q: What is the standard procedure for stopping Levikar-Mitim treatment?

A: Treatment is generally discontinued only under the direction of a qualified healthcare professional. Patients are cautioned against stopping the medicine suddenly without first consulting with their doctor.

Q: Is it possible for Levikar-Mitim to affect blood sugar levels?

A: The medicine is fundamentally involved in the body's metabolism of fats and carbohydrates. Clinical studies have investigated its potential to improve aspects of glucose metabolism, indicating this is a topic that is best addressed in discussion with a healthcare provider.

Q: Is Levikar-Mitim known to cause changes in appetite or weight?

A: Yes, regulatory safety documents have listed changes in appetite and body weight as less common or infrequent adverse reactions associated with the medicine. This is a factor that may be monitored during treatment.

Q: Why is it important to check the expiration date on Levikar-Mitim?

A: As with any prescription medicine, the expiration date is a vital regulatory marker that guarantees the product is fully potent and safe to use up to that time. Expired medicine is typically discarded in accordance with local pharmaceutical waste requirements.

Q: What is the risk of dependence or withdrawal associated with Levikar-Mitim?

A: Levocarnitine is not classified by regulatory bodies as a controlled substance and is not associated with abuse potential or dependence. However, discontinuation of treatment is typically done under a doctor's supervision.

Q: Does Levikar-Mitim affect the results of common lab tests?

A: Official warnings note that Levikar-Mitim can increase the International Normalized Ratio (INR) in patients who are also taking blood thinners like warfarin. For this reason, frequent laboratory monitoring of blood coagulation parameters is required. Regular lab tests are also often used to check carnitine levels.

Q: Is there a link between Levikar-Mitim and changes in mood?

A: Official safety data lists changes in mood, specifically depression, as a less common or infrequent adverse reaction that has been reported during treatment.

Q: Why might a patient need to stop taking Levikar-Mitim suddenly?

A: A doctor may advise a patient to stop taking the medicine immediately if a serious adverse event, such as a severe hypersensitivity reaction (like anaphylaxis or trouble breathing), occurs. These events are rare but are key safety concerns noted in official regulatory documents.

Q: If I am taking vitamins or supplements, could they interact with Levikar-Mitim?

A: Yes, according to drug interaction documents, co-administration of non-pharmaceutical forms, specifically D- or DL-carnitine, is restricted because it interferes with the active molecule. Additionally, the herbal product Rose Hips is noted to reduce the amount of the drug in the blood.

Q: What are the general rules for managing side effects from Levikar-Mitim?

A: Any side effects that occur are typically reported to a healthcare provider. Official literature notes that dose adjustments may help manage gastrointestinal side effects. Reducing the dosage has also been documented as a way to manage the dose-related adverse effect of body odor.

Q: Why do doctors recommend different duration times for Levikar-Mitim treatment?

A: The length of treatment is determined by the patient’s underlying condition, as documented in official indications. Treatment for primary carnitine deficiency is lifelong and chronic, while intravenous administration for an acute metabolic crisis is temporary, lasting only until the patient is clinically stable.

Q: Can someone who drives or operates machinery use Levikar-Mitim?

A: Official warnings advise caution for patients with a known history of seizures, as the frequency or severity of seizures may increase. Adverse reactions like headache and dizziness have also been reported, which may temporarily affect a person's ability to safely operate a vehicle or heavy machinery.

Q: How does the official literature describe the benefits of Levikar-Mitim?

A: The medicine is officially described as treating conditions that result from low carnitine levels. The benefit is rooted in its role as a carrier molecule that facilitates the entry of long-chain fatty acids into the mitochondria, thereby supporting energy production in high-energy tissues like the heart and muscle.

Q: Is it necessary to have routine check-ups while taking Levikar-Mitim?

A: Yes, routine check-ups and laboratory monitoring are generally required during treatment. Official documents specify that tests, such as checking serum carnitine levels, may be done. Monitoring is particularly necessary if the medicine is taken with certain blood thinners.

How should Levikar-Mitim be stored and disposed of?

Levikar-Mitim, containing the active ingredient Levocarnitine, must be stored under specific conditions to maintain product integrity, as directed by official regulatory labeling.

Required Storage and Handling

Condition
Temperature: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection: Protect from light and excessive heat. Do not freeze the medication.
Child Safety: Keep the product securely out of the reach of children and pets.

Stability and Disposal

Requirement
In-Use Stability: Any unused portion of an opened injectable vial must be discarded immediately, as it contains no preservative.
Container: Keep the product in its original, closed container (or outer carton for vials) until use.
Disposal: Dispose of all unused or expired medication in accordance with local requirements for pharmaceutical waste, which may involve drug take-back programs.

Levikar-Mitim